Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Unicycive Therapeutics (NASDAQ:UNCY) from a strong sell rating to a hold rating in a report published on Wednesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the company. HC Wainwright cut their price target on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Benchmark reaffirmed a “speculative buy” rating and set a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Guggenheim reiterated a “buy” rating and set a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Finally, B. Riley Financial restated a “buy” rating and set a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Unicycive Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock opened at $5.45 on Wednesday. The firm has a market cap of $151.78 million, a P/E ratio of -3.11 and a beta of 1.79. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $8.74. The stock’s 50 day moving average is $5.80 and its 200 day moving average is $6.61.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.41. Equities analysts anticipate that Unicycive Therapeutics will post -1.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Unicycive Therapeutics during the second quarter worth $55,000. Vanguard Group Inc. boosted its stake in Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after buying an additional 52,925 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Unicycive Therapeutics in the 3rd quarter worth approximately $512,000. Finally, Citadel Advisors LLC bought a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $182,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.